These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9685512

  • 21. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
    Hassager C, Jensen LT, Pødenphant J, Thomsen K, Christiansen C.
    Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
    [Abstract] [Full Text] [Related]

  • 22. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH, Eyre DR.
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [Abstract] [Full Text] [Related]

  • 23. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M, Zaki S, Sheiba M, El-Minawi AM.
    Clin Lab; 2003 Feb; 49(11-12):625-36. PubMed ID: 14651333
    [Abstract] [Full Text] [Related]

  • 24. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 25. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
    [Abstract] [Full Text] [Related]

  • 26. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.
    Scariano JK, Glew RH, Bou-Serhal CE, Clemens JD, Garry PJ, Baumgartner RN.
    Bone; 1998 Nov; 23(5):471-7. PubMed ID: 9823455
    [Abstract] [Full Text] [Related]

  • 27. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients.
    Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y.
    Clin Chem; 2005 Dec; 51(12):2312-7. PubMed ID: 16223890
    [Abstract] [Full Text] [Related]

  • 28. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 29. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
    Clemens JD, Herrick MV, Singer FR, Eyre DR.
    Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
    [Abstract] [Full Text] [Related]

  • 30. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2363-8. PubMed ID: 10404804
    [Abstract] [Full Text] [Related]

  • 31. Prednisolone Effects on Urine Cross-Linked N-Telopeptides of Type I Collagen (Ntx) Diurnal Rhythms in Children.
    Wolthers OD, Heuck C.
    Recent Pat Inflamm Allergy Drug Discov; 2018 Jul; 12(2):158-161. PubMed ID: 29366431
    [Abstract] [Full Text] [Related]

  • 32. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
    Bettica P, Bevilacqua M, Vago T, Masino M, Cucinotta E, Norbiato G.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
    [Abstract] [Full Text] [Related]

  • 33. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
    Wasnich RD, Ross PD, Thompson DE, Cizza G, Yates AJ.
    Osteoporos Int; 1999 Sep; 9(5):455-60. PubMed ID: 10550466
    [Abstract] [Full Text] [Related]

  • 34. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
    Pedrazzoni M, Alfano FS, Gatti C, Fantuzzi M, Girasole G, Campanini C, Basini G, Passeri M.
    Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
    [Abstract] [Full Text] [Related]

  • 35. Differences in bone resorption after menopause in Japanese women with normal or low bone mineral density: quantitation of urinary cross-linked N-telopeptides.
    Taguchi Y, Gorai I, Zhang MG, Chaki O, Nakayama M, Minaguchi H.
    Calcif Tissue Int; 1998 May; 62(5):395-9. PubMed ID: 9541516
    [Abstract] [Full Text] [Related]

  • 36. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
    Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M, Bianco P, Robey PG, Collins MT.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4133-40. PubMed ID: 25033066
    [Abstract] [Full Text] [Related]

  • 37. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
    Cryer B, Binkley N, Simonelli C, Lewiecki EM, Lanza F, Chen E, Petruschke RA, Mullen C, de Papp AE.
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):127-36. PubMed ID: 16257815
    [Abstract] [Full Text] [Related]

  • 38. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P, Stancíková M, Letkovská A, Rovenský J.
    Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
    [Abstract] [Full Text] [Related]

  • 39. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
    Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K.
    J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
    [Abstract] [Full Text] [Related]

  • 40. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K, Kamimura M, Hashidate H, Uchiyama S, Nakagawa H.
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.